Merck-AstraZeneca breast cancer drug Lynparza improves long-term survival, clinical trial shows

Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, has shown significant improvement in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.

Jaime Grajales Benjumea—Getty Images